enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Marginal Zone Lymphoma - Lymphoma Research Foundation

    lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/mzl

    Marginal zone lymphoma (MZL) is a group of indolent (slow growing) NHL B-cell lymphomas, which account for approximately eight percent of all NHL cases. The average age at diagnosis is 60 years, and it is slightly more common in women than in men.

  3. Understanding Lymphoma: Marginal Zone Lymphoma

    lymphoma.org/.../LRF_Understanding_Lymphoma_Marginal_Zone_Lymphoma_Fact_Sheet.pdf

    The Understanding Lymphoma fact sheet series is published by the Lymphoma Research Foundation (LRF ) for the purpose of informing and educating readers. Facts and Facts and statistics were obtained using published information, including d ata from the Surveillance, Epidemiology, and End Results (SEER) Progr am.

  4. Marginal Zone Lymphoma

    lymphoma.org/wp-content/uploads/2023/04/LRF_Marginal_Zone_Lymphoma_Factsheet.pdf

    Marginal zone lymphomas (MZLs) are a group of indolent (slow-growing) B-cell non-Hodgkin lymphomas (NHLs), beginning in a part of lymph tissue called the marginal zone, which account for approximately 5 to 10 percent of all NHL cases.

  5. Marginal Zone Lymphoma

    lymphoma.org/wp-content/uploads/2024/10/Marginal_Zone_Lymphoma_Fact_Sheet_2024.pdf

    MZL is the third most common indolent lymphoma and accounts for approximately 5 to 10% of all NHLs. The number of new cases of MZL increases with age, but the average age at diagnosis depends on the type of MZL (see below). Understanding Lymphoma and Chronic Lymphocytic Leukemia (CLL) Marginal Zone Lymphoma

  6. Marginal Zone Lymphoma: Treatment Options - LRF

    lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/mzl/mzltreatment

    Treatment selection for a patient with Marginal Zone Lymphoma (MZL) depends on the type, the stage and location of the disease, the patient’s age and overall health, and any lymphoma-related signs or symptoms.

  7. Marginal Zone Lymphoma: Relapsed/Refractory - LRF

    lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/mzl/relapsedmzl

    To learn about treatments under investigation for Marginal Zone Lymphoma, download the Marginal Zone Lymphoma Fact Sheet. Download the Clinical Trials Fact Sheet.

  8. 2024 Marginal Zone Lymphoma (MZL) Scientific Workshop...

    lymphoma.org/2024-marginal-zone-lymphoma-mzl-scientific-workshop-registration

    Get lymphoma and CLL resources and updates. Sign Up The Lymphoma Research Foundation’s mission is to realize the promise of science to eradicate lymphoma and serve the community touched by this disease.

  9. Marginal Zone Lymphoma: Long-Term Survivorship - LRF

    lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/mzl/mzlsurvivorship

    Marginal Zone Lymphoma: Long-term Survivorship. Patients in remission should have regular visits with a physician who is familiar with their medical history and the treatments they have received.

  10. MZL Patient Handout v4 021921 - Lymphoma

    lymphoma.org/wp-content/uploads/2021/04/TG-Corporate-MZL-Fact-Sheet-for...

    Lymphoma is the most common type of blood cancer and causes lymphocytes, a kind of white blood cell, to grow and multiply uncontrollably 1,2 • Around 90% of lymphomas are categorized as non-Hodgkin’s lymphoma (NHL) 1

  11. A LYMPHOMA RESEARCH FOUNDATION WHITE PAPER

    lymphoma.org/wp-content/uploads/2021/01/LRF-MZL-White-Paper-Final-Web.pdf

    In April of 2019, the Lymphoma Research Foundation (LRF) gathered international experts in the field of marginal zone lymphoma (MZL) in New York City for the inaugural International Scientific Workshop on Marginal Zone Lymphoma. MZL is an uncommon non-Hodgkin lymphoma with a typically indolent clinical course. The management of